Cargando…
Antifibrogenic Effects of the Antimicrobial Peptide Cathelicidin in Murine Colitis-Associated Fibrosis
BACKGROUND & AIMS: Cathelicidin (LL-37 in human and mCRAMP in mice) represents a family of endogenous antimicrobial peptides with anti-inflammatory effects. LL-37 also suppresses collagen synthesis, an important fibrotic response, in dermal fibroblasts. Here, we determined whether exogenous cath...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338438/ https://www.ncbi.nlm.nih.gov/pubmed/25729764 http://dx.doi.org/10.1016/j.jcmgh.2014.08.001 |
_version_ | 1782481214087626752 |
---|---|
author | Yoo, Jun Hwan Ho, Samantha Tran, Deanna Hoang-Yen Cheng, Michelle Bakirtzi, Kyriaki Kubota, Yuzu Ichikawa, Ryan Su, Bowei Tran, Diana Hoang-Ngoc Hing, Tressia C. Chang, Irene Shih, David Q. Issacson, Richard E. Gallo, Richard L. Fiocchi, Claudio Pothoulakis, Charalabos Koon, Hon Wai |
author_facet | Yoo, Jun Hwan Ho, Samantha Tran, Deanna Hoang-Yen Cheng, Michelle Bakirtzi, Kyriaki Kubota, Yuzu Ichikawa, Ryan Su, Bowei Tran, Diana Hoang-Ngoc Hing, Tressia C. Chang, Irene Shih, David Q. Issacson, Richard E. Gallo, Richard L. Fiocchi, Claudio Pothoulakis, Charalabos Koon, Hon Wai |
author_sort | Yoo, Jun Hwan |
collection | PubMed |
description | BACKGROUND & AIMS: Cathelicidin (LL-37 in human and mCRAMP in mice) represents a family of endogenous antimicrobial peptides with anti-inflammatory effects. LL-37 also suppresses collagen synthesis, an important fibrotic response, in dermal fibroblasts. Here, we determined whether exogenous cathelicidin administration modulates intestinal fibrosis in two animal models of intestinal inflammation and in human colonic fibroblasts. METHODS: C57BL/6J mice (n = 6 per group) were administered intracolonically with a trinitrobenzene sulphonic acid (TNBS) enema to induce chronic (6–7 weeks) colitis with fibrosis. We administered mCRAMP peptide (5 mg/kg every 3 day, week 5–7) or cathelicidin gene (Camp)-expressing lentivirus (10(7) infectious units week 4) intracolonically or intravenously, respectively. We then infected 129Sv/J mice with Salmonella typhimurium orally to induce cecal inflammation with fibrosis. Camp-expressing lentivirus (10(7) infectious units day 11) was administered intravenously. RESULTS: TNBS-induced chronic colitis was associated with increased colonic collagen (col1a2) mRNA expression. Intracolonic cathelicidin (mCRAMP peptide) administration or intravenous delivery of lentivirus-overexpressing cathelicidin gene significantly reduced colonic col1a2 mRNA expression in TNBS-exposed mice compared with vehicle administration. Salmonella infection also caused increased cecal inflammation associated with collagen (col1a2) mRNA expression that was prevented by intravenous delivery of Camp-expressing lentivirus. Exposure of human primary intestinal fibroblasts and human colonic CCD-18Co fibroblasts to transforming growth factor-β1 (TGF-β1) and/or insulin-like growth factor 1 induced collagen protein and mRNA expression, which was reduced by LL-37 (3–5 μM) through a MAP kinase-dependent mechanism. CONCLUSIONS: Cathelicidin can reverse intestinal fibrosis by directly inhibiting collagen synthesis in colonic fibroblasts. |
format | Online Article Text |
id | pubmed-4338438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-43384382016-01-01 Antifibrogenic Effects of the Antimicrobial Peptide Cathelicidin in Murine Colitis-Associated Fibrosis Yoo, Jun Hwan Ho, Samantha Tran, Deanna Hoang-Yen Cheng, Michelle Bakirtzi, Kyriaki Kubota, Yuzu Ichikawa, Ryan Su, Bowei Tran, Diana Hoang-Ngoc Hing, Tressia C. Chang, Irene Shih, David Q. Issacson, Richard E. Gallo, Richard L. Fiocchi, Claudio Pothoulakis, Charalabos Koon, Hon Wai Cell Mol Gastroenterol Hepatol Original Research BACKGROUND & AIMS: Cathelicidin (LL-37 in human and mCRAMP in mice) represents a family of endogenous antimicrobial peptides with anti-inflammatory effects. LL-37 also suppresses collagen synthesis, an important fibrotic response, in dermal fibroblasts. Here, we determined whether exogenous cathelicidin administration modulates intestinal fibrosis in two animal models of intestinal inflammation and in human colonic fibroblasts. METHODS: C57BL/6J mice (n = 6 per group) were administered intracolonically with a trinitrobenzene sulphonic acid (TNBS) enema to induce chronic (6–7 weeks) colitis with fibrosis. We administered mCRAMP peptide (5 mg/kg every 3 day, week 5–7) or cathelicidin gene (Camp)-expressing lentivirus (10(7) infectious units week 4) intracolonically or intravenously, respectively. We then infected 129Sv/J mice with Salmonella typhimurium orally to induce cecal inflammation with fibrosis. Camp-expressing lentivirus (10(7) infectious units day 11) was administered intravenously. RESULTS: TNBS-induced chronic colitis was associated with increased colonic collagen (col1a2) mRNA expression. Intracolonic cathelicidin (mCRAMP peptide) administration or intravenous delivery of lentivirus-overexpressing cathelicidin gene significantly reduced colonic col1a2 mRNA expression in TNBS-exposed mice compared with vehicle administration. Salmonella infection also caused increased cecal inflammation associated with collagen (col1a2) mRNA expression that was prevented by intravenous delivery of Camp-expressing lentivirus. Exposure of human primary intestinal fibroblasts and human colonic CCD-18Co fibroblasts to transforming growth factor-β1 (TGF-β1) and/or insulin-like growth factor 1 induced collagen protein and mRNA expression, which was reduced by LL-37 (3–5 μM) through a MAP kinase-dependent mechanism. CONCLUSIONS: Cathelicidin can reverse intestinal fibrosis by directly inhibiting collagen synthesis in colonic fibroblasts. Elsevier 2014-11-11 /pmc/articles/PMC4338438/ /pubmed/25729764 http://dx.doi.org/10.1016/j.jcmgh.2014.08.001 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). |
spellingShingle | Original Research Yoo, Jun Hwan Ho, Samantha Tran, Deanna Hoang-Yen Cheng, Michelle Bakirtzi, Kyriaki Kubota, Yuzu Ichikawa, Ryan Su, Bowei Tran, Diana Hoang-Ngoc Hing, Tressia C. Chang, Irene Shih, David Q. Issacson, Richard E. Gallo, Richard L. Fiocchi, Claudio Pothoulakis, Charalabos Koon, Hon Wai Antifibrogenic Effects of the Antimicrobial Peptide Cathelicidin in Murine Colitis-Associated Fibrosis |
title | Antifibrogenic Effects of the Antimicrobial Peptide Cathelicidin in Murine Colitis-Associated Fibrosis |
title_full | Antifibrogenic Effects of the Antimicrobial Peptide Cathelicidin in Murine Colitis-Associated Fibrosis |
title_fullStr | Antifibrogenic Effects of the Antimicrobial Peptide Cathelicidin in Murine Colitis-Associated Fibrosis |
title_full_unstemmed | Antifibrogenic Effects of the Antimicrobial Peptide Cathelicidin in Murine Colitis-Associated Fibrosis |
title_short | Antifibrogenic Effects of the Antimicrobial Peptide Cathelicidin in Murine Colitis-Associated Fibrosis |
title_sort | antifibrogenic effects of the antimicrobial peptide cathelicidin in murine colitis-associated fibrosis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338438/ https://www.ncbi.nlm.nih.gov/pubmed/25729764 http://dx.doi.org/10.1016/j.jcmgh.2014.08.001 |
work_keys_str_mv | AT yoojunhwan antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT hosamantha antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT trandeannahoangyen antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT chengmichelle antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT bakirtzikyriaki antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT kubotayuzu antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT ichikawaryan antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT subowei antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT trandianahoangngoc antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT hingtressiac antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT changirene antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT shihdavidq antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT issacsonricharde antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT gallorichardl antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT fiocchiclaudio antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT pothoulakischaralabos antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis AT koonhonwai antifibrogeniceffectsoftheantimicrobialpeptidecathelicidininmurinecolitisassociatedfibrosis |